Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Stadler
Walter M
WM
Michaelis
Laura C
LC
Ratain
Mark J
MJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis / Q000188:drug therapy*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen